<PAGE>


                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               FORM 10-KSB/A NO. 2

    [ ]    ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE
           SECURITIES EXCHANGE ACT OF 1934 [Fee Required]

           For the fiscal year ended _______________

    [X]     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
            SECURITIES EXCHANGE ACT OF 1934 [No fee required]

            For the transition period from January 1, 1996 to March 31, 1996

                             Amending Signature Page

                         Commission file number 0-26202

                     EASTBROKERS INTERNATIONAL INCORPORATED
                 (Name of small business issuer in its charter)


             Delaware                                 52-1807562
  (State or other jurisdiction of        (I.R.S. Employer Identification No.)
  incorporation or organization)

          15245 Shady Grove Road, Suite 340, Rockville, Maryland 20850
               (Address of principal executive offices) (Zip Code)

                                 (301) 527-1110
                (Issuer's telephone number, including area code)

                             CZECH INDUSTRIES, INC.
                   (Former name, if changed since last report)

    Securities registered under Section 12(b) of the Exchange Act: None.

    Securities registered under Section 12(g) of the Exchange Act:

                                  COMMON STOCK
                                CLASS A WARRANTS

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Check if there is no disclosure of delinquent  filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure  will be contained,  to
the  best  of  registrant's   knowledge,  in  definitive  proxy  or  information
statements  incorporated  by  reference  in Part III of this Form  10-KSB or any
amendment to this Form 10-KSB. [X ]

The issuer's revenue for the most recent fiscal year is $399,218.

The aggregate market value of the Common stock held by  non-affiliates  computed
by  reference  to the average bid and asked prices of such stock on May 31, 1996
was approximately $16,444,818.

As of June 1, 1996,  the Registrant  had 8,905,000  shares of Common Stock,  par
value $0.01, issued and outstanding.

Transitional Small Business Disclosure Format (Check One): Yes     No  X
                                                               ---    ---



<PAGE>


The 10-KSB for the  transition  period from January 1, 1996 to March 31, 1996 is
being amended to include Dr. Michael Sumichrast's signature in his capacity as a
director of the Company at the time of the original filing.


























                                     - 2 -
<PAGE>


                                   SIGNATURES

     In accordance  with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

(Registrant)            CZECH INDUSTRIES, INC.
             ------------------------------------------

By (Signature and Title)  /s/ Dr. Michael Sumichrast        Date   6/28/96
                        ----------------------------------       ----------
                              Dr. Michael Sumichrast,
                              Chairman of the Board

     In  accordance  with the Exchange Act, this report has been signed below by
the following  persons on behalf of the  registrant and in the capacities and on
the dates indicated.


By (Signature and Title)  /s/ Ing. Petr Bednarik            Date   6/28/96
                        ----------------------------------       ----------
                              Ing. Petr Bednarik,
                              Chief Executive Officer,
                              President, Director


By (Signature and Title)  /s/ Randall Greene                Date   6/28/96
                        ----------------------------------       ----------
                              Randall Greene, Director


By (Signature and Title)                                    Date
                        ----------------------------------       ----------
                              Ing. Petr Holub, Director


By (Signature and Title)                                    Date
                        ----------------------------------       ----------
                              Ing. Miroslav Kerous, Director


By (Signature and Title)                                    Date
                        ----------------------------------       ----------
                              Robert C, McFarlane, Director


By (Signature and Title)  /s/ Peter Schmid                  Date   6/28/96
                        ---------------------------------        ----------
                              Peter Schmid, Director


By (Signature and Title)  /s/ Martin A. Sumichrast          Date   6/28/96
                        ---------------------------------        ----------
                              Martin A. Sumichrast,
                              Chief Financial Officer,
                              Director


By (Signature and Title)                                    Date
                         ---------------------------------       ----------
                              JUDr. Dalibor Vitek, Director





                                      - 3 -

<PAGE>

                             SIGNATURES (Continued)

     In  accordance  with the Exchange Act, this report has been signed below by
the following  persons on behalf of the  registrant and in the capacities and on
the dates indicated.


By (Signature and Title)  /s/ Dr. Michael Sumichrast        Date   7/22/97
                        ----------------------------------       ----------
                              Dr. Michael Sumichrast,
                              Director

















                                     - 4 -